American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

Helicobacter pylori (H. pylori) remains a prevalent, worldwide, chronic infection. Though the prevalence of this infection appears to be decreasing in many parts of the world, H. pylori remains an important factor linked to the development of peptic ulcer disease, gastric malignanc and dyspeptic symptoms. Whether to test for H. pylori in patients with functional dyspepsia, gastroesophageal reflux disease (GERD), patients taking nonsteroidal antiinflammatory drugs, with iron deficiency anemia, or who are at greater risk of developing gastric cancer remains controversial. H. pylori can be diagnosed by endoscopic or nonendoscopic methods. A variety of factors including the need for endoscopy, pretest probability of infection, local availability, and an understanding of the performance characteristics and cost of the individual tests influences choice of evaluation in a given patient. Testing to prove eradication should be performed in patients who receive treatment of H. pylori for peptic ulcer disease, individuals with persistent dyspeptic symptoms despite the test-and-treat strategy, those with H. pylori-associated MALT lymphoma, and individuals who have undergone resection of early gastric cancer. Recent studies suggest that eradication rates achieved by first-line treatment with a proton pump inhibitor (PPI), clarithromycin, and amoxicillin have decreased to 70–85%, in part due to increasing clarithromycin resistance. Eradication rates may also be lower with 7 versus 14-day regimens. Bismuth-containing quadruple regimens for 7–14 days are another first-line treatment option. Sequential therapy for 10 days has shown promise in Europe but requires validation in North America. The most commonly used salvage regimen in patients with persistent H. pylori is bismuth quadruple therapy. Recent data suggest that a PPI, levofloxacin, and amoxicillin for 10 days is more effective and better tolerated than bismuth quadruple therapy for persistent H. pylori infection, though this needs to be validated in the United States.

[1]  M. Blaser,et al.  Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. , 1995, Gastroenterology.

[2]  A. Berstad,et al.  Reproducibility of the 14C urea breath test repeated after 1 week. , 1995, The American journal of gastroenterology.

[3]  F. Mégraud,et al.  Diagnosis of Helicobacter pylori Infection , 2006, Helicobacter.

[4]  L. Irwig,et al.  Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. , 1996, The American journal of gastroenterology.

[5]  M F Dixon,et al.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.

[6]  L. Laine,et al.  Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. , 1996, Gastrointestinal endoscopy.

[7]  D. Graham,et al.  The Best Gastric Site for Obtaining a Positive Rapid Urease Test , 1996, Helicobacter.

[8]  C. O'Morain,et al.  Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. , 1997, Scandinavian journal of gastroenterology.

[9]  W. Chey,et al.  Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. , 1997, The American journal of gastroenterology.

[10]  A. Blum,et al.  Lack of Effect of TreatingHelicobacter pyloriInfection in Patients with Nonulcer Dyspepsia , 1998 .

[11]  R. Knill-Jones,et al.  Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. , 1998, The New England journal of medicine.

[12]  Effect of standard and high dose ranitidine on [13c]urea breath test results , 1998 .

[13]  L. Laine,et al.  Effect of Proton-Pump Inhibitor Therapy on Diagnostic Testing for Helicobacter pylori , 1998, Annals of Internal Medicine.

[14]  N. Talley American Gastroenterological Association medical position statement: evaluation of dyspepsia. , 2005, Gastroenterology.

[15]  R. Hunt,et al.  Guidelines for the management of Helicobacter pylori infection , 1998, American Journal of Gastroenterology.

[16]  E. Brooks,et al.  Effect of Standard and High Dose Ranitidine on [13C]Urea Breath Test Results , 1998, American Journal of Gastroenterology.

[17]  P. Malfertheiner,et al.  Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting , 1999, American Journal of Gastroenterology.

[18]  F. Gomollón,et al.  Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1‐week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer , 1999, Alimentary pharmacology & therapeutics.

[19]  W. Chey,et al.  The 13C-urea blood test accurately detects active Helicobacter pylori infection: a United States, multicenter trial , 1999, American Journal of Gastroenterology.

[20]  F. Mandelli,et al.  Reversal of Iron Deficiency Anemia after Helicobacter pylori Eradication in Patients with Asymptomatic Gastritis , 1999, Annals of Internal Medicine.

[21]  Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting , 1999 .

[22]  W. Chey,et al.  A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection: a United States, multicenter trial , 1999, American Journal of Gastroenterology.

[23]  S. Kim,et al.  Randomized Placebo‐Controlled Trial of Helicobacter pylori Eradication for Iron‐Deficiency Anemia in Preadolescent Children and Adolescents , 1999, Helicobacter.

[24]  Shih-hung Huang,et al.  Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. , 1999, Gastrointestinal endoscopy.

[25]  L. Bravo,et al.  Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection , 1999, American Journal of Gastroenterology.

[26]  Colin-Jones Dg,et al.  Guidelines for the management of dyspepsia. , 1999 .

[27]  L. Laine,et al.  Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. , 2000, Gastrointestinal endoscopy.

[28]  Hoffman,et al.  Furazolidone combination therapies for Helicobacter pylori infection in the United States , 2000, Alimentary pharmacology & therapeutics.

[29]  H. Windsor,et al.  Accurate diagnosis of Helicobacter pylori. Polymerase chain reaction tests. , 2000, Gastroenterology clinics of North America.

[30]  N. Lehn,et al.  Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment: Preliminary Experience , 2000, Journal of clinical gastroenterology.

[31]  G. Perez-Perez,et al.  Accurate diagnosis of Helicobacter pylori. Culture, including transport. , 2000, Gastroenterology clinics of North America.

[32]  H. El-Zimaity Accurate diagnosis of Helicobacter pylori with biopsy. , 2000, Gastroenterology clinics of North America.

[33]  B. Marshall,et al.  Accurate diagnosis of Helicobacter pylori. Urease tests. , 2000, Gastroenterology clinics of North America.

[34]  N. Vakil,et al.  The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori , 2000, American Journal of Gastroenterology.

[35]  A. Andriulli,et al.  Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. , 2000, The New England journal of medicine.

[36]  F. Mégraud,et al.  HOW TO TREAT HELICOBACTER PYLORI , 2000 .

[37]  D. Metz,et al.  Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection , 2000, American Journal of Gastroenterology.

[38]  C. O'Morain,et al.  Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding , 2000, American Journal of Gastroenterology.

[39]  F. Mégraud,et al.  How to treat Helicobacter pylori. First-line, second-line, and future therapies. , 2000, Gastroenterology clinics of North America.

[40]  B. Marshall,et al.  Accurate diagnosis of Helicobacter pylori. Serologic testing. , 2000, Gastroenterology clinics of North America.

[41]  H. Windsor,et al.  ACCURATE DIAGNOSIS OF HELICOBACTER PYLOXI , 2000 .

[42]  A. Fendrick,et al.  Helicobacter pylori-related disease: guidelines for testing and treatment. , 2000, Archives of internal medicine.

[43]  W. Chey Accurate diagnosis of Helicobacter pylori. 14C-urea breath test. , 2000, Gastroenterology clinics of North America.

[44]  D. Graham,et al.  Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. , 2000, Gastroenterology clinics of North America.

[45]  Gené,et al.  A meta‐analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection , 2000, Alimentary pharmacology & therapeutics.

[46]  J. Everhart Recent developments in the epidemiology of Helicobacter pylori. , 2000, Gastroenterology clinics of North America.

[47]  Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection , 2000 .

[48]  S. Vigneri,et al.  Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori , 2001, American Journal of Gastroenterology.

[49]  W. Chey,et al.  Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice. , 2001, Archives of internal medicine.

[50]  P. Malfertheiner,et al.  A meta‐analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori‐associated gastric or duodenal ulcer , 2001, Alimentary pharmacology & therapeutics.

[51]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[52]  A. Andriulli,et al.  Randomized study of two “rescue” therapies for helicobacter pylori-infected patients after failure of standard triple therapies , 2001, American Journal of Gastroenterology.

[53]  N. Sato,et al.  Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. , 2001, Scandinavian journal of gastroenterology.

[54]  A. Sahai,et al.  Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage , 2001, Alimentary pharmacology & therapeutics.

[55]  J. Casellas,et al.  Comparison of diagnostic methods for Helicobacter pylori infection in patients with upper gastrointestinal bleeding. , 2001, Scandinavian journal of gastroenterology.

[56]  R. E. Smith,et al.  Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. , 2001, Ophthalmology.

[57]  C. Soussy,et al.  Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy , 2001, Alimentary pharmacology & therapeutics.

[58]  P. Hsu,et al.  Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer‐like functional dyspepsia , 2001, Alimentary pharmacology & therapeutics.

[59]  M. Färkkilä,et al.  Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia , 2001, American Journal of Gastroenterology.

[60]  G. Manes,et al.  Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy , 2001, Alimentary pharmacology & therapeutics.

[61]  B. Burnand,et al.  Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia , 2001, American Journal of Gastroenterology.

[62]  N. Talley,et al.  A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. , 2002, Gastroenterology.

[63]  C. O'Morain,et al.  Does Helicobacter pylori Eradication Affect Symptoms in Nonulcer Dyspepsia: A 5‐Year Follow‐Up Study , 2002, Helicobacter.

[64]  F. Nomura,et al.  Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy , 2002, American Journal of Gastroenterology.

[65]  R. Hopkins,et al.  Recovery Rate and Prognosis in Older Persons Who Develop Acute Lung Injury and the Acute Respiratory Distress Syndrome , 2002, Annals of Internal Medicine.

[66]  K. Lai,et al.  One‐week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies , 2002, Alimentary pharmacology & therapeutics.

[67]  L. Laine,et al.  Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies , 2002, American Journal of Gastroenterology.

[68]  R. Hopkins,et al.  Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 19931999 , 2002, Annals of Internal Medicine.

[69]  P. Hsu,et al.  Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients , 2002, Gut.

[70]  F. Perri,et al.  Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments , 2002, American Journal of Gastroenterology.

[71]  I. Maev,et al.  Furazolidone‐based triple ‘rescue therapy’ vs. quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole , 2002, Alimentary pharmacology & therapeutics.

[72]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[73]  J. Gisbert,et al.  The Stool Antigen Test for Detection of Helicobacter pylori after Eradication Therapy , 2002, Annals of Internal Medicine.

[74]  R. Hunt,et al.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis , 2002, The Lancet.

[75]  J. Gisbert,et al.  Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta‐analysis , 2002, Alimentary pharmacology & therapeutics.

[76]  D. Graham,et al.  Pearls and pitfalls of assessing Helicobacter pylori status. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[77]  D. Forman,et al.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews , 2003, American Journal of Gastroenterology.

[78]  D. Graham,et al.  Meta‐analysis: proton pump inhibitor or H2‐receptor antagonist for Helicobacter pylori eradication , 2003, Alimentary pharmacology & therapeutics.

[79]  F. Mégraud,et al.  Review article: the treatment of refractory Helicobacter pylori infection , 2003, Alimentary pharmacology & therapeutics.

[80]  D. Schilling,et al.  A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[81]  D. Graham,et al.  Salvage Therapy after Two or More Prior Helicobacter pylori Treatment Failures: the Super Salvage Regimen , 2003, Helicobacter.

[82]  L. Laine Is it time for quadruple therapy to be first line? , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[83]  G. Apseloff Severe neutropenia among healthy volunteers given rifabutin in clinical trials , 2003, Clinical pharmacology and therapeutics.

[84]  B. McMahon,et al.  The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections , 2003, Annals of Internal Medicine.

[85]  F. Mégraud,et al.  Which Test to Use to Detect Helicobacter pylori Infection in Patients With Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma? , 2003, American Journal of Gastroenterology.

[86]  C. Hassan,et al.  High eradication rates of Helicobacter pylori with a new sequential treatment , 2003, Alimentary pharmacology & therapeutics.

[87]  G. Gatz,et al.  Recent Use of Proton Pump Inhibitor‐Based Triple Therapies for the Eradication of H. pylori: A Broad Data Review , 2003, Helicobacter.

[88]  Lack of accuracy of the noninvasive stool antigen test in patients with gastroduodenal ulcer bleeding , 2003 .

[89]  W. Wong,et al.  Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second‐line treatment for Helicobacter pylori infection , 2003, Alimentary pharmacology & therapeutics.

[90]  Is it time for quadruple therapy to be first line , 2003 .

[91]  K. Haruma,et al.  The long‐term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis , 2003, Alimentary pharmacology & therapeutics.

[92]  P. Malfertheiner,et al.  Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia , 2003, Alimentary pharmacology & therapeutics.

[93]  J. Aparicio,et al.  Comparison of stool immunoassay with standard methods for detection of Helicobacter pylori infection in patients with upper‐gastrointestinal bleeding of peptic origin , 2003, European journal of gastroenterology & hepatology.

[94]  A. Gasbarrini,et al.  Meta‐analysis: the relationship between Helicobacter pylori infection and gastro‐oesophageal reflux disease , 2003, Alimentary pharmacology & therapeutics.

[95]  R. Hunt,et al.  Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North A , 2003, American Journal of Gastroenterology.

[96]  J. Gisbert,et al.  Meta‐analysis: comparative efficacy of different proton‐pump inhibitors in triple therapy for Helicobacter pylori eradication , 2003, Alimentary pharmacology & therapeutics.

[97]  D. Graham,et al.  Eradication of Helicobacter pylori by 7‐Day Triple‐Therapy Regimens Combining Pantoprazole with Clarithromycin, Metronidazole, or Amoxicillin in Patients with Peptic Ulcer Disease: Results of Two Double‐Blind, Randomized Studies , 2003, Helicobacter.

[98]  J. Gisbert,et al.  H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. , 2003, The Cochrane database of systematic reviews.

[99]  X. Calvet,et al.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis , 2003, Alimentary pharmacology & therapeutics.

[100]  Chia‐Long Lee,et al.  Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. , 2003, Archives of internal medicine.

[101]  A. Hungin,et al.  Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review , 2003, BMJ : British Medical Journal.

[102]  P. Malfertheiner,et al.  Antigen stool test for assessment of Helicobacter pylori infection in patients with upper gastrointestinal bleeding , 2003, Alimentary pharmacology & therapeutics.

[103]  D. Graham,et al.  Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors , 2003, American Journal of Gastroenterology.

[104]  L. Cohen,et al.  Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia , 2003, American Journal of Gastroenterology.

[105]  G. Tytgat,et al.  Lack of Accuracy of the Noninvasive Helicobacter pylori Stool Antigen Test in Patients With Gastroduodenal Ulcer Bleeding , 2003, American Journal of Gastroenterology.

[106]  J. Gisbert,et al.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta‐analysis , 2003, Alimentary pharmacology & therapeutics.

[107]  F. Perna,et al.  Effect of Proton Pump Inhibitors and Antacid Therapy on 13C Urea Breath Tests and Stool Test for Helicobacter Pylori Infection , 2004, American Journal of Gastroenterology.

[108]  A. Barkun,et al.  There is no difference in the disease severity of gastro‐oesophageal reflux disease between patients infected and not infected with Helicobacter pylori , 2004, Alimentary pharmacology & therapeutics.

[109]  M. Granström,et al.  Enzyme-Linked Immunosorbent Assay for Helicobacter pylori Needs Adjustment for the Population Investigated , 2004, Journal of Clinical Microbiology.

[110]  HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE IN CANADIAN POPULATIONS , 2004 .

[111]  D. Levine,et al.  Symptom Response and Healing of Erosive Esophagitis with Proton-Pump Inhibitors in Patients with Helicobacter pylori Infection , 2004, American Journal of Gastroenterology.

[112]  M. Sasatsu,et al.  Development of a Highly Sensitive Method for Detection of Clarithromycin-Resistant Helicobacter pylori from Human Feces , 2005, Current Microbiology.

[113]  J. Gisbert,et al.  Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer , 2004 .

[114]  Abdulmajeed Al Abdukareem Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.

[115]  N. Vakil,et al.  Seven‐day therapy for Helicobacter pylori in the United States , 2004, Alimentary pharmacology & therapeutics.

[116]  D. Forman,et al.  Eradication Therapy in Helicobacter pylori Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis , 2004, The American Journal of Gastroenterology.

[117]  A. Çelebi,et al.  Improvement of complete blood count in patients with iron deficiency anemia and Helicobacter pylori infection after the eradication of Helicobacter pylori. , 2004, Hepato-gastroenterology.

[118]  J. Lee,et al.  (Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China.) , 2004 .

[119]  A. Smout,et al.  Treatment of gastro‐oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? , 2004, Alimentary pharmacology & therapeutics.

[120]  L. Fischbach,et al.  Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies , 2004, Alimentary pharmacology & therapeutics.

[121]  Y. Ou,et al.  Helicobacter pylori stool antigen test in patients with bleeding peptic ulcers , 2004, Helicobacter.

[122]  J. Gisbert,et al.  Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review , 2004, Alimentary pharmacology & therapeutics.

[123]  F. Chan,et al.  Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication , 2004, Gut.

[124]  D. Graham,et al.  False Negative Urea Breath Tests with H2‐Receptor Antagonists: Interactions Between Helicobacter pylori Density and pH , 2004, Helicobacter.

[125]  J. Pandolfino,et al.  H. Pylori and GERD: Is Less More? , 2004, American Journal of Gastroenterology.

[126]  D. Metz,et al.  Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori–Infected Persons, United States , 2004, Emerging infectious diseases.

[127]  J. Gisbert,et al.  Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: a Systematic Review , 2004, Helicobacter.

[128]  D. Graham,et al.  Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[129]  J. Sung Should we eradicate Helicobacter pylori in non‐steroidal anti‐inflammatory drug users? , 2004, Alimentary pharmacology & therapeutics.

[130]  S. Leung,et al.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. , 2004, JAMA.

[131]  B. Ali Pharmacological, Therapeutic and Toxicological Properties of Furazolidone: Some Recent Research , 1999, Veterinary Research Communications.

[132]  S. Childs,et al.  The effect of Helicobacter pylori and its eradication on gastro‐oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis , 2004, Alimentary pharmacology & therapeutics.

[133]  D. Kearney,et al.  Iron-Deficiency Anemia and Helicobacter pylori Infection: A Review of the Evidence , 2005, The American Journal of Gastroenterology.

[134]  R. Owen,et al.  Real-time PCR detection and frequency of 16 S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales , 2005 .

[135]  R. Laheij,et al.  The importance of corpus biopsies for the determination of Helicobacter pylori infection. , 2005, The Netherlands journal of medicine.

[136]  G. Papatheodoridis,et al.  Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. , 2005, World journal of gastroenterology.

[137]  M. Stolte,et al.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  W. Chey,et al.  A clinician's guide to managing Helicobacter pylori infection. , 2005, Cleveland Clinic journal of medicine.

[139]  R. Gascoyne,et al.  Helicobacter pylori and MALT lymphoma. , 2005, Gastroenterology.

[140]  P. Malfertheiner,et al.  Helicobacter pylori Eradication Has the Potential to Prevent Gastric Cancer: A State-of-the-Art Critique , 2005, The American Journal of Gastroenterology.

[141]  M. Janssen,et al.  Meta‐analysis: the influence of pre‐treatment with a proton pump inhibitor on Helicobacter pylori eradication , 2005, Alimentary pharmacology & therapeutics.

[142]  C. Hassan,et al.  High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study , 2005, Alimentary pharmacology & therapeutics.

[143]  E. Cholongitas,et al.  MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. , 2005, World journal of gastroenterology.

[144]  C. O'Morain,et al.  Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients , 2005, Alimentary pharmacology & therapeutics.

[145]  J. Gisbert,et al.  Meta‐analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users , 2005, Alimentary pharmacology & therapeutics.

[146]  M. Passos,et al.  New once‐daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study , 2005, Alimentary pharmacology & therapeutics.

[147]  P. Toskes,et al.  Evaluation of the Ez‐HBT Helicobacter blood test to establish Helicobacter pylori eradication , 2005, Alimentary pharmacology & therapeutics.

[148]  Geun Ho Kang,et al.  Impact of Clarithromycin Resistance on Eradication of Helicobacter pylori in Infected Adults , 2005, Antimicrobial Agents and Chemotherapy.

[149]  E. Fontham,et al.  Long term follow up of patients treated for Helicobacter pylori infection , 2005, Gut.

[150]  H. Matsumoto,et al.  Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment , 2005, Cancer.

[151]  N. Talley,et al.  Guidelines for the Management of Dyspepsia , 2005, The American Journal of Gastroenterology.

[152]  J. J. Tai,et al.  Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. , 2005, Journal of the National Cancer Institute.

[153]  A. Francavilla,et al.  Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. , 2005, Gastroenterology.

[154]  F. Chan NSAID-Induced Peptic Ulcers and Helicobacter pylori Infection , 2005, Drug safety.

[155]  R. Owen,et al.  Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales. , 2005, The Journal of antimicrobial chemotherapy.

[156]  F. Mégraud,et al.  Should We Eradicate Helicobacter pylori Before Prescribing an NSAID? Result of a Placebo-Controlled Study , 2005, The American Journal of Gastroenterology.

[157]  L. Laine,et al.  The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later. , 2005, Gastrointestinal endoscopy.

[158]  F. Perna,et al.  Diagnostic accuracy of a new rapid urease test (Pronto Dry), before and after treatment of Helicobacter pylori infection. , 2005, Minerva gastroenterologica e dietologica.

[159]  R. Testa,et al.  A study of 4‐ and 7‐day triple therapy with rabeprazole, high‐dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication , 2006, Alimentary pharmacology & therapeutics.

[160]  A. Opekun,et al.  Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas‐Mexican border , 2006, Alimentary pharmacology & therapeutics.

[161]  L. Marzio,et al.  Role of the Preliminary Susceptibility Testing for Initial and After Failed Therapy of Helicobacter pylori Infection with Levofloxacin, Amoxicillin, and Esomeprazole , 2006, Helicobacter.

[162]  J. Gisbert,et al.  Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures , 2006, The American Journal of Gastroenterology.

[163]  J. Gisbert,et al.  Accuracy of Monoclonal Stool Antigen Test for the Diagnosis of H. pylori Infection: A Systematic Review and Meta-Analysis , 2006, The American Journal of Gastroenterology.

[164]  B. Gessner,et al.  Endemic Iron Deficiency Associated With Helicobacter pylori Infection Among School-Aged Children in Alaska , 2006, Pediatrics.

[165]  M. Kasuga,et al.  Primary Levofloxacin Resistance and gyrA/B Mutations Among Helicobacter pylori in Japan , 2006, Helicobacter.

[166]  R. Hunt,et al.  The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis , 2006, The American Journal of Gastroenterology.

[167]  J. Gisbert,et al.  Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure , 2006, Alimentary pharmacology & therapeutics.

[168]  F. Perna,et al.  Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial , 2005, Gut.

[169]  J. Sánchez-Delgado,et al.  Usefulness of a delayed test for the diagnosis of Helicobacter pylori infection in bleeding peptic ulcer , 2006, Alimentary pharmacology & therapeutics.

[170]  F. Norman,et al.  Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond , 2006, Expert review of anticancer therapy.

[171]  T. Borody,et al.  Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection , 2006, Alimentary pharmacology & therapeutics.

[172]  Víctor Abraira,et al.  Accuracy of Helicobacter pylori Diagnostic Tests in Patients with Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis , 2006, The American Journal of Gastroenterology.

[173]  M. Stolte,et al.  Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro‐oesophageal reflux disease in Western patients with non‐ulcer dyspepsia , 2006, Alimentary pharmacology & therapeutics.

[174]  C. Hassan,et al.  Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real‐time polymerase chain reaction , 2006, Alimentary pharmacology & therapeutics.

[175]  G. Papatheodoridis,et al.  Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[176]  K. Matsuo,et al.  Systematic review and meta‐analysis: importance of CagA status for successful eradication of Helicobacter pylori infection , 2006, Alimentary pharmacology & therapeutics.

[177]  K. Gebo Implications for Patient Management , 2006 .

[178]  C. Hassan,et al.  Clarithromycin-Resistant Genotypes and Eradication of Helicobacter pylori , 2006, Annals of Internal Medicine.

[179]  Ziding Feng,et al.  A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska. , 2006, The Journal of infectious diseases.

[180]  R. Meier,et al.  Increased Rate of Helicobacter pylori Infection Detected by PCR in Biopsies With Chronic Gastritis , 2006, The American journal of surgical pathology.

[181]  W. Chey,et al.  Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis , 2006, The American Journal of Gastroenterology.

[182]  M. Stolte,et al.  Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin , 2006, Alimentary pharmacology & therapeutics.

[183]  C. Hassan,et al.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[184]  W. Chey,et al.  Primary care physician perceptions of non‐steroidal anti‐inflammatory drug and aspirin‐associated toxicity: results of a national survey , 2006, Alimentary pharmacology & therapeutics.

[185]  F. Nardi,et al.  2‐Week Triple Therapy for Helicobacter pylori Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study , 2006, Helicobacter.

[186]  D. Forman,et al.  Eradication of Helicobacter pylori for non-ulcer dyspepsia. , 2006, The Cochrane database of systematic reviews.

[187]  Y. Glupczynski,et al.  Prevalence and Mechanisms of Resistance to Fluoroquinolones in Helicobacter pylori Strains from Patients Living in Belgium , 2006, Helicobacter.

[188]  D. Graham,et al.  Iron deficiency and Helicobacter pylori infection in the United States. , 2006, American journal of epidemiology.

[189]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.